NEW YORK — Evotec and Indivumed said on Thursday that they have formed a new drug-discovery and -development alliance focused on non-small cell lung cancer.
Under the deal, the companies will use Evotec's bioinformatics analysis platform and drug discovery technologies with Indivumed's IndivuType database, which integrates patients' clinical information with genomic, transcriptomic, proteomic, and digital histopathology data derived from biospecimens.
Both firms will invest in data analysis, target identification, validation, and subsequent drug discovery. Evotec will be responsible for subsequent partnering of the programs and drug-discovery platform.
Additional terms were not disclosed.
The alliance comes almost a year after the Hamburg, Germany-based companies partnered to discover and develop precision treatments for colorectal cancer. That deal, they said, has yielded several new drug targets.
"We are confident that combining the highly complementary strengths of our companies will generate innovative drug candidates for clearly defined patient populations within non-small cell lung cancer who urgently need effective treatments," Evotec CSO Cord Dohrmann said in a statement.